ArticleOncotarget2017
Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial.Frontiers of medicine · 2023Trial
- Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial.Frontiers of medicine · 2023Trial
- Postoperative adjuvant therapy for stage IA-IIA cervical adenocarcinoma (FIGO 2018) with one intermediate-risk factor: a multicentre retrospective cohort study of 63,926 cases.World journal of surgical oncology · 2025Article
- Comparison of postoperative adjuvant platinum-based chemotherapy and no further therapy after radical surgery in intermediate-risk early-stage cervical cancer.Journal of gynecologic oncology · 2025Article
- Efficacy and safety of chemotherapy as monotherapy in patients with recurrent intermediate/high-risk factors following radical hysterectomy for stage IB-IIA cervical cancer: a single-center retrospective analysis.BMC women's health · 2024Article
- Heterogeneous treatment effects of adjuvant therapy for patients with cervical cancer in the intermediate-risk group.Cancer medicine · 2023Article
- A novel predictor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors.Gynecologic oncology reports · 2023Article
- Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group.International journal of clinical oncology · 2022Article
- Observational
- The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines evaluation committee.Journal of gynecologic oncology · 2021Article
- The baseline recurrence risk of patients with intermediate-risk cervical cancer.Obstetrics & gynecology science · 2021Article
- Evaluation of adjuvant chemotherapy after abdominal trachelectomy for cervical cancer: a single-institution experience.International journal of clinical oncology · 2021Article
- Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor.Journal of gynecologic oncology · 2020Article
- Phase 1/2 study of concurrent chemoradiotherapy with weekly irinotecan hydrochloride for advanced/recurrence uterine cancer: A multi-institutional study of Kansai Clinical Oncology Group.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020Article
- Fertility-sparing trachelectomy for early-stage cervical cancer: A proposal of an ideal candidate.Gynecologic oncology · 2020Article
- Significance of Malignant Peritoneal Cytology on the Survival of Women with Early-Stage Cervical Cancer: A Japanese Gynecologic Oncology Group Study.Journal of clinical medicine · 2019Article
- Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2019Article
- Association of Radical Hysterectomy Surgical Volume and Survival for Early-Stage Cervical Cancer.Obstetrics and gynecology · 2019Article
- Asian Society of Gynecologic Oncology International Workshop 2018.Journal of gynecologic oncology · 2019Article
- Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the effectiveness of systemic chemotherapy following radical hysterectomy for women with intermediate-risk stage IB cervical cancer. MATERIALS AND
methodsThis is a retrospective analysis of a previously organized nation-wide cohort study examining 6,003 women with stage IB-IIB cervical cancer who underwent radical hysterectomy between 2004 and 2008 in Japan. Survival of 555 women with stage IB cervical cancer in the intermediate-risk group (deep stromal invasion > 50%, large tumor size > 4 cm, and lympho-vascular space invasion [LVSI]) were examined based on adjuvant therapy patterns: chemotherapy alone (
resultsThe most common intermediate-risk pattern was LVSI with deep stromal invasion (
conclusionsOur study suggests that systemic chemotherapy may be an alternative treatment choice for adjuvant therapy in intermediate-risk stage IB cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.